Last reviewed · How we verify
anti-PD-L1 antibody
anti-PD-L1 antibody is a Small molecule drug developed by Lee's Pharmaceutical Limited. It is currently in Phase 1 development. Also known as: ZKAB001, Socazolimab Injection.
At a glance
| Generic name | anti-PD-L1 antibody |
|---|---|
| Also known as | ZKAB001, Socazolimab Injection |
| Sponsor | Lee's Pharmaceutical Limited |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ Trial (PHASE2)
- Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial (PHASE2, PHASE3)
- Comparing the New Anti-cancer Drug Eribulin With Chemotherapy Against the Usual Chemotherapy Alone in Metastatic Urothelial Cancer (PHASE3)
- Immunotherapy Biomarkers to Predict First-line PD(L)1-based Immunotherapy Response and Selection of Second-line Treatment in Stage IIIB-IV Non-small Cell Lung Cancer, IMMUNO-BIOMAP Trial (PHASE2)
- Study of Retinfanlimab in Combination With INCAGN02385 and INCAGN02390 as First-Line Treatment in Participants With PD-L1-Positive (CPS ≥ 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (PHASE2)
- A Study of Atezolizumab Versus Placebo as Adjuvant Therapy in Participants With High-risk Muscle-invasive Bladder Cancer (MIBC) Who Are ctDNA Positive Following Cystectomy (PHASE3)
- Testing the Addition of Radiation Therapy to the Usual Treatment (Immunotherapy With or Without Chemotherapy) for Advanced Stage Non-small Cell Lung Cancer Patients Who Are PD-L1 Negative (PHASE2, PHASE3)
- A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitecan Versus Standard of Care in the Treatment of Advanced Urothelial Cancer (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- anti-PD-L1 antibody CI brief — competitive landscape report
- anti-PD-L1 antibody updates RSS · CI watch RSS
- Lee's Pharmaceutical Limited portfolio CI
Frequently asked questions about anti-PD-L1 antibody
What is anti-PD-L1 antibody?
anti-PD-L1 antibody is a Small molecule drug developed by Lee's Pharmaceutical Limited.
Who makes anti-PD-L1 antibody?
anti-PD-L1 antibody is developed by Lee's Pharmaceutical Limited (see full Lee's Pharmaceutical Limited pipeline at /company/lee-s-pharmaceutical-limited).
Is anti-PD-L1 antibody also known as anything else?
anti-PD-L1 antibody is also known as ZKAB001, Socazolimab Injection.
What development phase is anti-PD-L1 antibody in?
anti-PD-L1 antibody is in Phase 1.
Related
- Manufacturer: Lee's Pharmaceutical Limited — full pipeline
- Also known as: ZKAB001, Socazolimab Injection
- Compare: anti-PD-L1 antibody vs similar drugs
- Pricing: anti-PD-L1 antibody cost, discount & access